Jason M. Melear

1.1k total citations
56 papers, 354 citations indexed

About

Jason M. Melear is a scholar working on Genetics, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Jason M. Melear has authored 56 papers receiving a total of 354 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Genetics, 26 papers in Oncology and 25 papers in Pathology and Forensic Medicine. Recurrent topics in Jason M. Melear's work include Chronic Lymphocytic Leukemia Research (28 papers), Lymphoma Diagnosis and Treatment (24 papers) and Monoclonal and Polyclonal Antibodies Research (10 papers). Jason M. Melear is often cited by papers focused on Chronic Lymphocytic Leukemia Research (28 papers), Lymphoma Diagnosis and Treatment (24 papers) and Monoclonal and Polyclonal Antibodies Research (10 papers). Jason M. Melear collaborates with scholars based in United States, Germany and Switzerland. Jason M. Melear's co-authors include John M. Burke, Jeff P. Sharman, Habte Yimer, Suzanne Fanning, Mohit Narang, Göran B. Klintmalm, David Andorsky, Marlon F. Levy, George J. Netto and Ernesto P. Molmenti and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Jason M. Melear

52 papers receiving 349 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jason M. Melear United States 10 203 131 131 109 92 56 354
Tuan S. Nguyen United States 10 150 0.7× 133 1.0× 60 0.5× 48 0.4× 41 0.4× 19 338
Leylah Drusbosky United States 13 223 1.1× 198 1.5× 105 0.8× 47 0.4× 43 0.5× 72 522
Sotirios Sachanas Greece 12 146 0.7× 111 0.8× 109 0.8× 209 1.9× 158 1.7× 34 384
Mercedes Gironella Spain 11 149 0.7× 135 1.0× 199 1.5× 71 0.7× 89 1.0× 46 355
Kerry Taylor United States 7 116 0.6× 69 0.5× 139 1.1× 99 0.9× 48 0.5× 12 295
Giulia Marzocchi Italy 8 98 0.5× 128 1.0× 234 1.8× 26 0.2× 97 1.1× 25 324
Dolores Caballero Spain 9 123 0.6× 107 0.8× 305 2.3× 112 1.0× 124 1.3× 17 428
Atsushi Isoda Japan 10 158 0.8× 73 0.6× 96 0.7× 139 1.3× 42 0.5× 27 321
Dipti Patel‐Donnelly United States 13 197 1.0× 130 1.0× 146 1.1× 216 2.0× 133 1.4× 27 433
David H. Vesole United States 9 195 1.0× 178 1.4× 164 1.3× 196 1.8× 144 1.6× 30 444

Countries citing papers authored by Jason M. Melear

Since Specialization
Citations

This map shows the geographic impact of Jason M. Melear's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jason M. Melear with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jason M. Melear more than expected).

Fields of papers citing papers by Jason M. Melear

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jason M. Melear. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jason M. Melear. The network helps show where Jason M. Melear may publish in the future.

Co-authorship network of co-authors of Jason M. Melear

This figure shows the co-authorship network connecting the top 25 collaborators of Jason M. Melear. A scholar is included among the top collaborators of Jason M. Melear based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jason M. Melear. Jason M. Melear is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Manda, Sudhir, Bertrand Anz, Christopher B. Benton, et al.. (2024). A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia. Hematological Oncology. 42(3). e3274–e3274. 6 indexed citations
2.
Castillo, Jorge J., Edwin Kingsley, Mohit Narang, et al.. (2023). Zanubrutinib in patients with treatment‐naïve or relapsed/refractory Waldenström macroglobulinemia: An expanded‐access study of 50 patients in the United States. SHILAP Revista de lepidopterología. 4(1). 301–304. 3 indexed citations
3.
Goldlust, Samuel, Jong Hee Chang, Yoshitaka Narita, et al.. (2023). Ombipepimut dosing emulsion (ODE) + bevacizumab (bev) vs bev alone in patients (pts) with recurrent or progressive glioblastoma (rGBM).. Journal of Clinical Oncology. 41(16_suppl). 2022–2022. 1 indexed citations
4.
Lansigan, Frederick, David Andorsky, Morton Coleman, et al.. (2021). Completed Induction Phase Analysis of Magnify: Phase 3b Study of Lenalidomide + Rituximab (R 2) Followed By Maintenance in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma. Blood. 138(Supplement 1). 812–812. 11 indexed citations
5.
Manda, Sudhir, Bertrand Anz, Christopher B. Benton, et al.. (2021). Treatment Initiation of Venetoclax in Combination with Azacitidine or Decitabine in an Outpatient Setting in Patients with Untreated Acute Myeloid Leukemia. Blood. 138(Supplement 1). 1265–1265. 3 indexed citations
6.
Plummer, Ruth, Emma Dean, Hendrik‐Tobias Arkenau, et al.. (2021). A phase 1b study evaluating the safety and preliminary efficacy of berzosertib in combination with gemcitabine in patients with advanced non-small cell lung cancer. Lung Cancer. 163. 19–26. 26 indexed citations
7.
Sharman, Jeffrey P., Jason M. Melear, Abdulraheem Yacoub, et al.. (2021). INDUCTION R2 FOLLOWED BY MAINTENANCE IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: INTERIM ANALYSIS FROM THE PHASE 3B MAGNIFY STUDY. Hematological Oncology. 39(S2). 1 indexed citations
8.
Hoffman, James E., Brea Lipe, Jason M. Melear, et al.. (2021). SEA-BCMA, an Investigational Nonfucosylated Monoclonal Antibody: Ongoing Results of a Phase 1 Study in Patients with Relapsed/Refractory Multiple Myeloma (SGNBCMA-001). Blood. 138(Supplement 1). 2740–2740. 6 indexed citations
9.
Adjei, Alex A., Muhammad S. Beg, Jason M. Melear, et al.. (2020). 536MO A phase I, first-in-human, safety, pharmacokinetic, and pharmacodynamic study of oral dubermatinib (TP-0903) in patients with advanced solid tumours. Annals of Oncology. 31. S469–S469. 1 indexed citations
10.
Andorsky, David, Morton Coleman, Abdulraheem Yacoub, et al.. (2020). MAGNIFY phase IIIb interim analysis of induction R2 followed by maintenance in relapsed/refractory indolent NHL.. Journal of Clinical Oncology. 38(15_suppl). 8046–8046. 8 indexed citations
11.
Coleman, Morton, David Andorsky, Abdulraheem Yacoub, et al.. (2020). Patients with Relapsed/Refractory Marginal Zone Lymphoma in the MAGNIFY Phase IIIb Interim Analysis of Induction R2 Followed By Maintenance. Blood. 136(Supplement 1). 24–25. 4 indexed citations
12.
Flinn, Ian W., David Andorsky, Jason M. Melear, et al.. (2020). Debulking Regimens Prior to Initiating Venetoclax Therapy in Untreated Patients with Chronic Lymphocytic Leukemia: Interim Results from a Phase 3b Study. Blood. 136(Supplement 1). 4–5. 2 indexed citations
13.
Shah, Nirav N., Amrita Krishnan, Nina Shah, et al.. (2019). Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with Advanced B-Cell Malignancies. Blood. 134(Supplement_1). 5329–5329. 16 indexed citations
14.
Rummel, Mathias, David Andorsky, Morton Coleman, et al.. (2019). PS1253 MAGNIFY: PHASE IIIB INTERIM ANALYSIS OF INDUCTION #R2 FOLLOWED BY MAINTENANCE IN PATIENTS WITH RELAPSED/REFRACTORY INDOLENT NON‐HODGKIN LYMPHOMA. HemaSphere. 3(S1). 572–572. 1 indexed citations
15.
16.
Yimer, Habte, Jason M. Melear, Edward A. Faber, et al.. (2018). Lyra: A Phase 2 Study of Daratumumab (Dara) Plus Cyclophosphamide, Bortezomib, and Dexamethasone (Cybord) in Newly Diagnosed and Relapsed Patients (Pts) with Multiple Myeloma (MM). Blood. 132(Supplement 1). 152–152. 9 indexed citations
17.
Barr, Paul M., Stephen D. Smith, Mark Roschewski, et al.. (2018). Acalabrutinib combined with PI3Kδ inhibitor ACP-319 in patients (pts) with relapsed/refractory (R/R) B-cell malignancies.. Journal of Clinical Oncology. 36(15_suppl). 7518–7518. 5 indexed citations
18.
19.
20.
Melear, Jason M., Robert M. Goldstein, Marlon F. Levy, et al.. (2002). Hematologic aspects of liver transplantation for Budd-Chiari syndrome with special reference to myeloproliferative disorders1. Transplantation. 74(8). 1090–1095. 50 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tuan S. Nguyen Breakdown of academic impact, for papers by Leylah Drusbosky Breakdown of academic impact, for papers by Sotirios Sachanas Breakdown of academic impact, for papers by Mercedes Gironella Breakdown of academic impact, for papers by Kerry Taylor Breakdown of academic impact, for papers by Giulia Marzocchi Breakdown of academic impact, for papers by Dolores Caballero Breakdown of academic impact, for papers by Atsushi Isoda Breakdown of academic impact, for papers by Dipti Patel‐Donnelly Breakdown of academic impact, for papers by David H. Vesole
Rankless by CCL
2026